Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Otto CM, Rieser TM, Brooks MB, et alEvidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:1500–1504.
-
2.
Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005;15:9–16.
-
3.
Weinkle TK, Center SA, Randolph JF, et alEvaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993–2002). J Am Vet Med Assoc 2005;226:1869–1880.
-
4.
LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986–1987). J Am Vet Med Assoc 1990;197:1368–1372.
-
5.
Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985–1995. J Vet Intern Med 1999;13:338–345.
-
6.
Van Winkle TJ, Hackner SG, Liu SM. Clinical and pathological features of aortic thromboembolism in 36 dogs. J Vet Emerg Crit Care 1993;3:13–21.
-
7.
Littman MP, Dambach DM, Vaden SL, et alFamilial proteinlosing enteropathy and protein-losing nephropathy in Soft Coated Wheaten Terriers: 222 cases (1983–1997). J Vet Intern Med 2000;14:68–80.
-
8.
Moore KE, Morris N, Dhupa N, et alRetrospective study of streptokinase administration in 46 cats with arterial thromboembolism. J Vet Emerg Crit Care 2000;10:245–257.
-
9.
Hwang DH. Species variation in platelet aggregation. In: Longnecker GL, ed. The platelets, physiology and pharmacology. New York: Academic Press Inc, 1985;289–305.
-
10.
Brainard BM, Meredith CP, Callan MB, et alChanges in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res 2007;68:251–257.
-
11.
Yusuf S, Zhao F, Mehta SR, et alEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
-
12.
Hogan DF, Andrews DA, Green HW, et alAntiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc 2004;225:1406–1411.
-
13.
Wong PC, Crain EJ, Watson CA, et alClopidogrel versus prasugrel in rabbits—effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009;101:108–115.
-
14.
Coomber BL, Mitchell GB, Starr AE, et alClopidogrel induced suppression of bovine platelet activation in vitro and a preliminary study of its effect on the development of Mannheimia haemolytica induced pneumonia. Vet J 2006;171:126–134.
-
15.
Hong TT, Huang J, Driscoll E, et alThe antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 2005;46:526–533.
-
16.
Pereillo JM, Maftouh M, Andrieu A, et alStructure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288–1295.
-
17.
Savi P, Pereillo JM, Uzabiaga MF, et alIdentification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891–896.
-
18.
Mega JL, Close SL, Wiviott SD, et alCytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–362.
-
19.
Simon T, Verstuyft C, Mary-Krause M, et alGenetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–375.
-
20.
Chauret N, Gauthier A, Martin J, et alIn vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997;25:1130–1136.
-
21.
Bahrami G, Mohammadi B, Sisakhtnezhad S. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in the human serum: application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2008;864:168–172.
-
22.
Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.
-
23.
Craft RM, Chavez JJ, Bresee SJ, et alA novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004;143:301–309.
-
24.
United States Pharmacopeial Convention. General chapter 621. Chromatography. In: The United States pharmacopeia and the national formulary. USP 32–NF 27. Rockville, Md: US Pharmacopeial Convention, 2009;865–867.
-
25.
Xiang YZ, Kang LY, Gao XM, et alStrategies for antiplatelet targets and agents. Thromb Res 2008;123:35–49.
-
26.
Storey RF, Sanderson HM, White AE, et alThe central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925–934.
-
27.
Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366–1375.
-
28.
Lang T, Toller W, Gütl M, et alDifferent effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004;2:147–153.
-
29.
Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005;31:150–161.
-
30.
Hechler B, Eckly A, Ohlmann P, et alThe P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998;103:858–866.
-
31.
Feher G, Feher A, Pusch G, et alThe genetics of antiplatelet drug resistance. Clin Genet 2009;75:1–18.
-
32.
Heptinstall S, Glenn JR, May JA, et alClopidogrel resistance. Catheter Cardiovasc Interv 2004;63:397–398.
-
33.
Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G-protein dysfunction. J Clin Invest 1993;92:2469–2479.
-
34.
Weber A, Braun M, Hohlfeld T, et alRecovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001;52:333–336.
-
35.
Heilmann E, Friese P, Anderson S, et alBiotinylated blood platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993;85:729–735.
-
36.
Ho PM, Peterson ED, Wang L, et alIncidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome (Erratum published in JAMA 2008;299:2390). JAMA 2008;299:532–539.
-
37.
Narita T, Sato R, Motoishi K, et alThe interaction between orally administered non-steroidal anti-inflammatory drugs and prednisolone in healthy dogs. J Vet Med Sci 2007;69:353–363.
-
38.
Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 2006;41:533–539.
Advertisement
Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs
Abstract
Objective—To determine pharmacodynamic and pharmacokinetic properties of clopidogrel and the metabolite SR 26334 in dogs.
Animals—9 mixed-breed dogs.
Procedures—8 dogs received clopidogrel (mean ± SD 1.13 ± 0.17 mg/kg, PO, q 24 h) for 3 days; 5 of these dogs subsequently received a lower dose of clopidogrel (0.5 ± 0.18 mg/kg, PO, q 24 h) for 3 days. Later, 5 dogs received clopidogrel (1.09 ± 0.12 mg/kg, PO, q 24 h) for 5 days. Blood samples were collected for optical platelet aggregometry, citrated native and platelet mapping thrombelastography (TEG), and measurement of plasma drug concentrations. Impedance aggregometry was performed on samples from 3 dogs in each 3-day treatment group.
Results—ADP-induced platelet aggregation decreased (mean ± SD 93 ± 6% and 80 ± 22% of baseline values, respectively) after 72 hours in dogs in both 3-day treatment groups; duration of effect ranged from > 3 to > 7 days. Platelet mapping TEG and impedance aggregometry yielded similar results. Citrated native TEG was not different among groups. Clopidogrel was not detected in any samples; in dogs given 1.13 ± 0.17 mg/kg, maximum concentration of SR 26334 (mean ± SD, 0.206 ± 0.2 μg/mL) was detected 1 hour after administration.
Conclusions and Clinical Relevance—Clopidogrel inhibited ADP-induced platelet aggregation in healthy dogs and may be a viable antiplatelet agent for use in dogs.
Impact for Human Medicine—Pharmacodynamic effects of clopidogrel in dogs were similar to effects reported in humans; clopidogrel may be useful in studies involving dogs used to investigate human disease.
Contributor Notes
Supported by the Morris Animal Foundation (MAF D07CA-303) and the University of Georgia Clinical Research Committee.
Presented in abstract form at the American College of Veterinary Internal Medicine Forum, San Antonio, Tex, June 2008.
Powered by PubFactory